Cargando…

A Spectrum of Histomorphological and Immunohistochemical Expression Profiles of S-100, CD56 and Calretinin in Benign Peripheral Nerve Sheath Tumours

Introduction: Peripheral nerve sheath tumours comprise benign tumours; namely schwannomas and neurofibromas, and only rarely comprise hybrid benign tumours and their malignant counterpart, malignant peripheral nerve sheath tumours (MPNST). There may be diagnostic difficulties in histopathology analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaiswal, Poornima, CD, Anand, John, Jaison Jacob
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361631/
https://www.ncbi.nlm.nih.gov/pubmed/37485115
http://dx.doi.org/10.7759/cureus.40751
_version_ 1785076258222112768
author Jaiswal, Poornima
CD, Anand
John, Jaison Jacob
author_facet Jaiswal, Poornima
CD, Anand
John, Jaison Jacob
author_sort Jaiswal, Poornima
collection PubMed
description Introduction: Peripheral nerve sheath tumours comprise benign tumours; namely schwannomas and neurofibromas, and only rarely comprise hybrid benign tumours and their malignant counterpart, malignant peripheral nerve sheath tumours (MPNST). There may be diagnostic difficulties in histopathology analysis, especially in core needle biopsies where there is a limited amount of tissue. Immunohistochemistry (IHC) can play a beneficial role, especially in atypical and cellular histological variants and rarely hybrid tumours. Methods: A total of 45 cases of benign peripheral nerve sheath tumours were included in the study; there were 27 cases of neurofibroma including variants like plexiform and cellular neurofibromas and 18 cases of schwannomas including variants like ancient schwannoma and cellular schwannoma. Immunohistochemical staining (IHC) on these tumour tissues using S-100, CD56 and calretinin was done and scoring was done based on extent and intensity. Results and discussion: No significant differences were observed between neurofibromas and schwannomas on patient age and anatomical locations of these tumours. IHC results did not show statistically significant patterns of expression of S-100 protein between the schwannoma and neurofibromas groups (p=0.75). CD56 protein was expressed strongly (3+) in 90% of cases of schwannoma and negative in 86% of neurofibromas, the differential expression between the two groups was found to be statistically significant (p <0.0001). Calretinin was positive in 39% of schwannomas including one case of cellular schwannoma and negative in all (100%) cases of neurofibroma while the differential expression of calretinin between schwannoma and neurofibroma groups was found to be statistically significant (p < 0.005). Conclusion: Our study shows that S-100 does not show differential expression between schwannomas and neurofibromas. CD56 could be a potentially useful IHC marker to aid in the diagnosis of peripheral nerve sheath tumours with significantly higher expression in schwannomas compared to neurofibromas. Calretinin was also found to be preferentially expressed in schwannomas, though the difference is statistically significantly lower compared to CD56. A panel of all these markers could be used for accurate diagnosis.
format Online
Article
Text
id pubmed-10361631
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-103616312023-07-22 A Spectrum of Histomorphological and Immunohistochemical Expression Profiles of S-100, CD56 and Calretinin in Benign Peripheral Nerve Sheath Tumours Jaiswal, Poornima CD, Anand John, Jaison Jacob Cureus Neurology Introduction: Peripheral nerve sheath tumours comprise benign tumours; namely schwannomas and neurofibromas, and only rarely comprise hybrid benign tumours and their malignant counterpart, malignant peripheral nerve sheath tumours (MPNST). There may be diagnostic difficulties in histopathology analysis, especially in core needle biopsies where there is a limited amount of tissue. Immunohistochemistry (IHC) can play a beneficial role, especially in atypical and cellular histological variants and rarely hybrid tumours. Methods: A total of 45 cases of benign peripheral nerve sheath tumours were included in the study; there were 27 cases of neurofibroma including variants like plexiform and cellular neurofibromas and 18 cases of schwannomas including variants like ancient schwannoma and cellular schwannoma. Immunohistochemical staining (IHC) on these tumour tissues using S-100, CD56 and calretinin was done and scoring was done based on extent and intensity. Results and discussion: No significant differences were observed between neurofibromas and schwannomas on patient age and anatomical locations of these tumours. IHC results did not show statistically significant patterns of expression of S-100 protein between the schwannoma and neurofibromas groups (p=0.75). CD56 protein was expressed strongly (3+) in 90% of cases of schwannoma and negative in 86% of neurofibromas, the differential expression between the two groups was found to be statistically significant (p <0.0001). Calretinin was positive in 39% of schwannomas including one case of cellular schwannoma and negative in all (100%) cases of neurofibroma while the differential expression of calretinin between schwannoma and neurofibroma groups was found to be statistically significant (p < 0.005). Conclusion: Our study shows that S-100 does not show differential expression between schwannomas and neurofibromas. CD56 could be a potentially useful IHC marker to aid in the diagnosis of peripheral nerve sheath tumours with significantly higher expression in schwannomas compared to neurofibromas. Calretinin was also found to be preferentially expressed in schwannomas, though the difference is statistically significantly lower compared to CD56. A panel of all these markers could be used for accurate diagnosis. Cureus 2023-06-21 /pmc/articles/PMC10361631/ /pubmed/37485115 http://dx.doi.org/10.7759/cureus.40751 Text en Copyright © 2023, Jaiswal et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Neurology
Jaiswal, Poornima
CD, Anand
John, Jaison Jacob
A Spectrum of Histomorphological and Immunohistochemical Expression Profiles of S-100, CD56 and Calretinin in Benign Peripheral Nerve Sheath Tumours
title A Spectrum of Histomorphological and Immunohistochemical Expression Profiles of S-100, CD56 and Calretinin in Benign Peripheral Nerve Sheath Tumours
title_full A Spectrum of Histomorphological and Immunohistochemical Expression Profiles of S-100, CD56 and Calretinin in Benign Peripheral Nerve Sheath Tumours
title_fullStr A Spectrum of Histomorphological and Immunohistochemical Expression Profiles of S-100, CD56 and Calretinin in Benign Peripheral Nerve Sheath Tumours
title_full_unstemmed A Spectrum of Histomorphological and Immunohistochemical Expression Profiles of S-100, CD56 and Calretinin in Benign Peripheral Nerve Sheath Tumours
title_short A Spectrum of Histomorphological and Immunohistochemical Expression Profiles of S-100, CD56 and Calretinin in Benign Peripheral Nerve Sheath Tumours
title_sort spectrum of histomorphological and immunohistochemical expression profiles of s-100, cd56 and calretinin in benign peripheral nerve sheath tumours
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361631/
https://www.ncbi.nlm.nih.gov/pubmed/37485115
http://dx.doi.org/10.7759/cureus.40751
work_keys_str_mv AT jaiswalpoornima aspectrumofhistomorphologicalandimmunohistochemicalexpressionprofilesofs100cd56andcalretinininbenignperipheralnervesheathtumours
AT cdanand aspectrumofhistomorphologicalandimmunohistochemicalexpressionprofilesofs100cd56andcalretinininbenignperipheralnervesheathtumours
AT johnjaisonjacob aspectrumofhistomorphologicalandimmunohistochemicalexpressionprofilesofs100cd56andcalretinininbenignperipheralnervesheathtumours
AT jaiswalpoornima spectrumofhistomorphologicalandimmunohistochemicalexpressionprofilesofs100cd56andcalretinininbenignperipheralnervesheathtumours
AT cdanand spectrumofhistomorphologicalandimmunohistochemicalexpressionprofilesofs100cd56andcalretinininbenignperipheralnervesheathtumours
AT johnjaisonjacob spectrumofhistomorphologicalandimmunohistochemicalexpressionprofilesofs100cd56andcalretinininbenignperipheralnervesheathtumours